Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday, after the biopharmaceutical company said its ASCENIV treatment of primary humoral immunodeficiency disease (PIDD) was approved by the Food and Drug Administration. Trading volume jumped to 3.6 million shares, compared with the full-day average of about 577,000 shares, and enough to make the stock the most actively traded before the open. ADMA said late Monday that expect to have ASCENIV available for commercial launch during the second half of 2019. "With the receipt of ASCENIV's™ FDA approval, ADMA, at its sole option, can elect to access up to an additional $27.5M of available funding from Perceptive Advisors under ADMA's existing credit facility," said Chief Executive Adam Grossman. The stock has soared 77.3% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 16.1% and the S&P 500 has gained 14.4%.